Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Centessa PharmaceuticalsCNTA 12 Pretax Margin % is % as of Mar. 2026. GuruFocus rates CNTA with a GF Score™ of 12/100. The stock has 4 warning signs investors should review. Among 941 Biotechnology companies, Centessa Pharmaceuticals ranks worse than 106269.82% on this metric.
The historical rank and industry rank for Centessa Pharmaceuticals's Pretax Margin % or its related term are showing as below:
CNTA's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.42 * Ranked among companies with meaningful Pretax Margin % only.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Centessa Pharmaceuticals Pretax Margin % Related Terms
Centessa Pharmaceuticals Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CNTA vs CGON, LGND, COGT: Pretax Margin % Comparison
For the Biotechnology subindustry, Centessa Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Centessa Pharmaceuticals Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Centessa Pharmaceuticals's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Centessa Pharmaceuticals's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Centessa Pharmaceuticals (CNTA) has a Pretax Margin % of % as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Centessa Pharmaceuticals and its competitors. According to the industry distribution chart, Centessa Pharmaceuticals ranks #999999 out of 941 companies in the Biotechnology industry.
Is Centessa Pharmaceuticals' Pretax Margin % too high?
Centessa Pharmaceuticals' current Pretax Margin % is %. Based on the distribution chart, Centessa Pharmaceuticals ranks #999999 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Centessa Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Centessa Pharmaceuticals' Pretax Margin % compare to CGON and LGND?
According to the Biotechnology industry distribution chart, Centessa Pharmaceuticals ranks #999999 out of 941 companies for Pretax Margin %. This places Centessa Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Centessa Pharmaceuticals and its competitors. Centessa Pharmaceuticals's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Centessa Pharmaceuticals stock overvalued right now?
Centessa Pharmaceuticals (CNTA) has a current Pretax Margin % of %. The current Pretax Margin % is %. Centessa Pharmaceuticals' overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Centessa Pharmaceuticals (CNTA), the current Pretax Margin % is % as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.
12GF Score
Get the complete analysis for CNTA
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CNTA has been successfully added to your 
